Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

BACKGROUND: In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma. Per protocol, patients received KRd for a maximum of 18 cycles fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Hematol Oncol
Hauptverfasser: Dimopoulos, Meletios, Wang, Michael, Maisnar, Vladimir, Minarik, Jiri, Bensinger, William, Mateos, Maria-Victoria, Obreja, Mihaela, Blaedel, Julie, Moreau, Philippe
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2018
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5883881/
https://ncbi.nlm.nih.gov/pubmed/29615082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0583-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge